Labeling of Highly Reactive Tetrazines using [18F]SuFEx

Umberto M. Battisti; Marius Müller; Rocío García-Vázquez; Matthias Manfred Herth

doi:10.1055/a-2147-9303

Synlett, Table of Contents

Synlett 2024; 35(19): 2207-2211
DOI: 10.1055/a-2147-9303

letter

Isotopic Labeling

Labeling of Highly Reactive Tetrazines using [¹⁸F]SuFEx

Umberto M. Battisti ‡

^aDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, 2100 Copenhagen, Denmark

,

Marius Müller‡

^aDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, 2100 Copenhagen, Denmark

^bDepartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

,

Rocío García-Vázquez

^aDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, 2100 Copenhagen, Denmark

^bDepartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

,

Matthias Manfred Herth∗

^aDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, 2100 Copenhagen, Denmark

^bDepartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

› Author Affiliations

Abstract

All articles of this category

Abstract

Pretargeted imaging is an emerging technique to study the in vivo biodistribution of nanomedicines. Currently, the tetrazine ligation is considered the most promising bioorthogonal reaction for pretargeting. Recently, Zheng et al. described an ultrafast late-stage radiolabeling of tetrazines based on sulfur ¹⁸F-fluoride exchange click chemistry ([¹⁸F]SuFEx). However, bispyridyl and H-tetrazines—the most promising structures for in vivo pretargeted applications—cannot be labeled using the proposed reaction conditions as they lead to decomposition of the tetrazine core. Here, we report improved conditions, exploiting basic preconditioning conditions for the quaternary methyl ammonium (QMA) cartridge and the use of low basic anions that allow ¹⁸F-labeling of bispyridyl and H-tetrazines using SuFEx. This strategy resulted in fast and efficient radiolabeling of highly reactive tetrazines with radiochemical conversions of up to 85% and radiochemical purity above 95%. This opens up the possibility to use SuFEx to ¹⁸F-label tetrazines, which are suitable for in vivo pretargeted imaging.

Key words

fluorine-18 - SuFEx - tetrazine - radiochemistry - bioorthogonal chemistry

Full Text

References

References
1 Devaraj NK. ACS Cent. Sci. 2018; 4: 952
2 Hang HC, Yu C, Kato DL, Bertozzi CR. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 14846

3a Zeglis BM, Brand C, Abdel-Atti D, Carnazza KE, Cook BE, Carlin SD, Reiner T, Lewis JS. Mol. Pharmaceutics 2015; 12: 3575
3b Nguyen SS, Prescher JA. Nat. Rev. Chem. 2020; 4: 476
3c van Onzen AH. A. M, Versteegen RM, Hoeben FJ. M, Filot IA. W, Rossin R, Zhu T, Wu J, Hudson PJ, Janssen HM, ten Hoeve W, Robillard MS. J. Am. Chem. Soc. 2020; 142: 10955
3d Yang B, Kwon K, Jana S, Kim S, Avila-Crump S, Tae G, Mehl RA, Kwon I. Bioconjugate Chem. 2020; 31: 2456
3e Battisti UM, Bratteby K, Jorgensen JT, Hvass L, Shalgunov V, Mikula H, Kjær A, Herth MM. J. Med. Chem. 2021; 64: 15297
3f Smeenk ML, Agramunt J, Bonger KM. Curr. Opin. Chem. Biol. 2021; 60: 79

4 Rossin R, Verkerk PR, van den Bosch SM, Vulders RC. M, Verel I, Lub J, Robillard MS. Angew. Chem. Int. Ed. 2010; 49: 3238
5 Stéen EJ. L, Jorgensen JT, Denk C, Battisti UM, Norregaard K, Edem PE, Bratteby K, Shalgunov V, Wilkovitsch M, Svatunek D, Poulie CB. M, Hvass L, Simon M, Wanek T, Rossin R, Robillard M, Kristensen JL, Mikula H, Kjaer A, Herth MM. ACS Pharmacol. Transl. Sci. 2021; 4, 824
6 Stéen EJ. L, Edem PE, Nørregaard K, Jørgensen JT, Shalgunov V, Kjaer A, Herth MM. Biomaterials 2018; 179: 209
7 García-Vázquez R, Battisti UM, Herth MM. Pharmaceuticals 2022; 15: 685
8 Selvaraj R, Fox JM. Curr. Opin. Chem. Biol. 2013; 17: 753
9 Rossin R, Läppchen T, Bosch SM. v. d, Laforest R, Robillard MS. J. Nucl. Med. 2013; 54: 1989
10 Jacobson O, Kiesewetter DO, Chen X. Bioconjugate Chem. 2015; 26, 1
11 Stéen EJ. L, Jørgensen JT, Johann K, Nørregaard K, Sohr B, Svatunek D, Birke A, Shalgunov V, Edem PE, Rossin R, Seidl C, Schmid F, Robillard MS, Kristensen JL, Mikula H, Barz M, Kjær A, Herth MM. ACS Nano 2020; 14: 568
12 Denk C, Svatunek D, Filip T, Wanek T, Lumpi D, Fröhlich J, Kuntner C, Mikula H. Angew. Chem. Int. Ed. 2014; 53: 9655

13a Li Z, Cai H, Hassink M, Blackman ML, Brown RC. D, Conti PS, Fox JM. Chem. Commun. 2010; 46: 8043
13b Devaraj NK, Thurber GM, Keliher EJ, Marinelli B, Weissleder R. Proc. Natl. Acad. Sci. USA 2012; 109: 4762
13c Knight JC, Richter S, Wuest M, Way JD, Wuest F. Org. Biomol. Chem. 2013; 11: 3817
13d Zhu J, Li S, Wängler C, Wängler B, Lennox RB, Schirmacher R. Chem. Commun. 2015; 51: 12415
13e Meyer J.-P, Houghton JL, Kozlowski P, Abdel-Atti D, Reiner T, Pillarsetty NV. K, Scholz WW, Zeglis BM, Lewis JS. Bioconjugate Chem. 2016; 27: 298
13f Keinänen O, Li X.-G, Chenna NK, Lumen D, Ott J, Molthoff CF. M, Sarparanta M, Helariutta K, Vuorinen T, Windhorst AD. ACS Med. Chem. Lett. 2016; 7: 62
13g García-Vázquez R, Battisti UM, Jørgensen JT, Shalgunov V, Hvass L, Stares DL, Petersen IN, Crestey F, Löffler A, Svatunek D, Kristensen JL, Mikula H, Kjaer A, Herth MM. Chem. Sci. 2021; 12: 11668

14 Bratteby K, Shalgunov V, Battisti UM, Petersen IN, van den Broek SL, Ohlsson T, Gillings N, Erlandsson M, Herth MM. ACS Pharmacol. Transl. Sci. 2021; 4: 1556

15a Otaru S, Paulus A, Imlimthan S, Kuurne I, Virtanen H, Liljenbäck H, Tolvanen T, Auchynnikava T, Roivainen A, Helariutta K, Sarparanta M, Airaksinen AJ. Bioconjugate Chem. 2022; 33: 1393
15b Beaufrez J, Guillouet S, Seimbille Y, Perrio C. Pharmaceuticals 2023; 16: 636

16 Zheng Q, Xu H, Wang H, Du W.-GH, Wang N, Xiong H, Gu Y, Noodleman L, Sharpless KB, Yang G, Wu P. J. Am. Chem. Soc. 2021; 143: 3753
17 Dong J, Krasnova L, Finn MG, Sharpless KB. Angew. Chem. Int. Ed. 2014; 53: 9430
18 Barrow AS, Smedley CJ, Zheng Q, Li S, Dong J, Moses JE. Chem. Soc. Rev. 2019; 48: 4731

19a Kitamura S, Zheng Q, Woehl JL, Solania A, Chen E, Dillon N, Hull MV, Kotaniguchi M, Cappiello JR, Kitamura S, Nizet V, Sharpless KB, Wolan DW. J. Am. Chem. Soc. 2020; 142: 10899
19b Lucas SW, Qin RZ, Rakesh KP, Kumar KS. S, Qin H.-L. Bioorg. Chem. 2023; 130: 106227

20 Herth MM, Ametamey S, Antuganov D, Bauman A, Berndt M, Brooks AF, Bormans G, Choe YS, Gillings N, Häfeli UO, James ML, Kopka K, Kramer V, Krasikova R, Madsen J, Mu L, Neumaier B, Piel M, Rösch F, Ross T, Schibli R, Scott PJ. H, Shalgunov V, Vasdev N, Wadsak W, Zeglis BM. Nucl. Med. Biol. 2021; 93: 19

21a Walter N, Bertram J, Drewes B, Bahutski V, Timmer M, Schütz MB, Krämer F, Neumaier F, Endepols H, Neumaier B, Zlatopolskiy BD. Eur. J. Med. Chem. 2022; 237: 114383
21b Liu Z, Sun Y, Liu T. Front. Chem. 2022; 10

22 Vlastara M, Rossin R, Hoeben FJ. M, Roode KE. d, Boswinkel M, Kleijn LH. J, Nagarajah J, Rijpkema M, Robillard MS. bioRxiv 2023; preprint
23 Battisti UM, García-Vázquez R, Svatunek D, Herrmann B, Löffler A, Mikula H, Herth MM. Bioconjugate Chem. 2022; 33: 608
24 Qu Y, Sauvage F.-X, Clavier G, Miomandre F, Audebert P. Angew. Chem. Int. Ed. 2018; 57: 12057
25 García-Vázquez R, Jørgensen JT, Bratteby KE, Shalgunov V, Hvass L, Herth MM, Kjær A, Battisti UM. Pharmaceuticals 2022; 15: 245
26 General procedure for manual synthesis: To the dry [¹⁸F]fluoride was added a mixture of the selected compound (0.0099 mmol) in dry MeCN/DMF (0.5 mL). The reaction was left at room temperature, and quenched with H₂O (0.1 mL) after 5 min. Aliquots of the reaction were taken after 1 and 5 min. The aliquots were added to H₂O + 0.1% TFA (0.1 mL) and analyzed by radio-HPLC.
27 General procedure for automated synthesis: A solution of either the selected tetrazine (0.5 μmol) in dry MeCN (0.5 mL) or in dry DMF (0.5 mL) was added to the reaction vial containing the dried [¹⁸F]Bu₄NF (5.0–6.0 GBq), after being cooled with compressed air to room temperature for 8 min. The reaction was left at room temperature for 30 sec, before being immediately quenched with 0.3 mL of H₂O + 0.1 % TFA. The crude reaction was then purified via semi-preparative HPLC. Formulation of the product was obtained by diluting the collected fraction with Milli-Q H₂O (1:20) and trapping the resulting solution on a C18 solid-phase extraction cartridge. Subsequently, the C18 solid-phase extraction cartridge was washed with Milli-Q H₂O (7 mL), and the compound was eluted with EtOH (1 mL), followed by concentration under continuous N₂ flow at r.t. The resulting dry [¹⁸F]-tetrazine was dissolved in phosphate buffer, resulting in an activity concentration of 100 MBq/mL.

Supplementary Material

Supporting Information